The complementary role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in diagnosis of Hodgkin's lymphoma

Masoud, Rokia; Ibrahiem, Afaf T.; Tantawy, Dina; El-Dosoky, Ibrahim

doi:10.1016/j.anndiagpath.2019.06.006

Cited by 5 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGF2BP3 exhibits a strong expression in lymphoid malignancies such as B cell lymphomas of a germinal center origin [10,11]. It is expressed in Reed-Sternberg cells and can be used as a supplementary diagnostic marker in Hodgkin's lymphoma [12][13][14]. Increased expression of IGF2BP3 is associated with proliferative features in many solid tumors, mantle cell lymphoma, and chronic myeloid leukemia blast crisis [7,15,16], and promotes cell survival during ionizing radiation in B-cells [17].…”

Section: Introductionmentioning

confidence: 99%

IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia

Mäkinen

Nikkilä

Haapaniemi

et al. 2021

Cancers

View full text Add to dashboard Cite

The oncofetal protein insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) belongs to a family of RNA-binding proteins involved in localization, stability, and translational regulation of target RNAs. IGF2BP3 is used as a diagnostic and prognostic marker in several malignancies. Although the prognosis of pediatric B-cell acute lymphoblastic leukemia (B-ALL) has improved, a subgroup of patients exhibits high-risk features and suffer from disease recurrence. We sought to identify additional biomarkers to improve diagnostics, and we assessed expression of IGF2BP3 in a population-based pediatric cohort of B-ALL using a tissue microarray platform. The majority of pediatric B-ALL cases were positive for IGF2BP3 immunohistochemistry and were associated with an increased proliferative phenotype and activated STAT5 signaling pathway. Two large gene expression data sets were probed for the expression of IGF2BP3—the highest levels were seen among the B-cell lymphomas of a germinal center origin and well-established (KMT2A-rearranged and ETV6-RUNX1) and novel subtypes of B-ALL (e.g., NUTM1 and ETV6-RUNX1-like). A high mRNA for IGF2BP3 was associated with a proliferative “metagene” signature and a high expression of CDK6 in B-ALL. A low expression portended inferior survival in a high-risk cohort of pediatric B-ALL. Overall, our results show that IGF2BP3 shows subtype-specificity in expression and provides prognostic utility in high-risk B-ALL.

show abstract